Influence of gut and lung dysbiosis on lung cancer progression and their modulation as promising therapeutic targets: a comprehensive review

Thapa, R; Magar, AT; Shrestha, J; Panth, N; Idrees, S; Sadaf, T; Bashyal, S; Elwakil, BH; Sugandhi, VV; Rojekar, S; Nikhate, R; Gupta, G; Singh, SK; Dua, K; Hansbro, PM; Paudel, KR

Influence of gut and lung dysbiosis on lung cancer progression and their modulation as promising therapeutic targets: a comprehensive review

Thapa, R Magar, AT Shrestha, J Panth, N Idrees, S Sadaf, T Bashyal, S Elwakil, BH Sugandhi, VV Rojekar, S Nikhate, R Gupta, G Singh, SK Dua, K Hansbro, PM Paudel, KR

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: MedComm, 2024, 5, (12)
Issue Date:: 2024-12

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (2.21 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Thapa, R
dc.contributor.author	Magar, AT
dc.contributor.author	Shrestha, J
dc.contributor.author	Panth, N
dc.contributor.author	Idrees, S
dc.contributor.author	Sadaf, T
dc.contributor.author	Bashyal, S
dc.contributor.author	Elwakil, BH
dc.contributor.author	Sugandhi, VV
dc.contributor.author	Rojekar, S
dc.contributor.author	Nikhate, R
dc.contributor.author	Gupta, G
dc.contributor.author	Singh, SK
dc.contributor.author	Dua, K
dc.contributor.author	Hansbro, PM
dc.contributor.author	Paudel, KR
dc.date.accessioned	2024-11-25T04:54:46Z
dc.date.available	2024-11-25T04:54:46Z
dc.date.issued	2024-12
dc.identifier.citation	MedComm, 2024, 5, (12)
dc.identifier.issn	2688-2663
dc.identifier.issn	2688-2663
dc.identifier.uri	http://hdl.handle.net/10453/182101
dc.description.abstract	<jats:title>Abstract</jats:title><jats:p>Lung cancer (LC) continues to pose the highest mortality and exhibits a common prevalence among all types of cancer. The genetic interaction between human eukaryotes and microbial cells plays a vital role in orchestrating every physiological activity of the host. The dynamic crosstalk between gut and lung microbiomes and the gut–lung axis communication network has been widely accepted as promising factors influencing LC progression. The advent of the 16s rDNA sequencing technique has opened new horizons for elucidating the lung microbiome and its potential pathophysiological role in LC and other infectious lung diseases using a molecular approach. Numerous studies have reported the direct involvement of the host microbiome in lung tumorigenesis processes and their impact on current treatment strategies such as radiotherapy, chemotherapy, or immunotherapy. The genetic and metabolomic cross‐interaction, microbiome‐dependent host immune modulation, and the close association between microbiota composition and treatment outcomes strongly suggest that designing microbiome‐based treatment strategies and investigating new molecules targeting the common holobiome could offer potential alternatives to develop effective therapeutic principles for LC treatment. This review aims to highlight the interaction between the host and microbiome in LC progression and the possibility of manipulating altered microbiome ecology as therapeutic targets.</jats:p>
dc.language	en
dc.publisher	Wiley
dc.relation	International Association for the Study of Lung Cancer Foundation
dc.relation.ispartof	MedComm
dc.relation.isbasedon	10.1002/mco2.70018
dc.rights	info:eu-repo/semantics/openAccess
dc.title	Influence of gut and lung dysbiosis on lung cancer progression and their modulation as promising therapeutic targets: a comprehensive review
dc.type	Journal Article
utslib.citation.volume	5
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Inflammation (CFI)
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
dc.date.updated	2024-11-25T04:54:44Z
pubs.issue	12
pubs.publication-status	Published online
pubs.volume	5
utslib.citation.issue	12

Abstract:

AbstractLung cancer (LC) continues to pose the highest mortality and exhibits a common prevalence among all types of cancer. The genetic interaction between human eukaryotes and microbial cells plays a vital role in orchestrating every physiological activity of the host. The dynamic crosstalk between gut and lung microbiomes and the gut–lung axis communication network has been widely accepted as promising factors influencing LC progression. The advent of the 16s rDNA sequencing technique has opened new horizons for elucidating the lung microbiome and its potential pathophysiological role in LC and other infectious lung diseases using a molecular approach. Numerous studies have reported the direct involvement of the host microbiome in lung tumorigenesis processes and their impact on current treatment strategies such as radiotherapy, chemotherapy, or immunotherapy. The genetic and metabolomic cross‐interaction, microbiome‐dependent host immune modulation, and the close association between microbiota composition and treatment outcomes strongly suggest that designing microbiome‐based treatment strategies and investigating new molecules targeting the common holobiome could offer potential alternatives to develop effective therapeutic principles for LC treatment. This review aims to highlight the interaction between the host and microbiome in LC progression and the possibility of manipulating altered microbiome ecology as therapeutic targets.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/182101